Seven Healthcare Industry "High Reliability Organization Champions" Recognized by Patient Safety Movement Foundation
10.11.2021 16:00:00 EET | Business Wire | Press release
Medical errors claim the lives of nearly three million individuals across the globe every year. In any other high-risk industry, like aviation and nuclear power, these numbers would not be acceptable. Yet, the healthcare industry has continued to allow these events to occur—putting patients and staff at risk. The Patient Safety Movement Foundation (PSMF), a global non-profit committed to achieving zero preventable patient harm and death across the globe by 2030, believes that to reach this goal healthcare organizations that provide care to patients need to commit to operating as highly reliable organizations (HROs) to reduce preventable medical harm. To support this, PSMF launched its new HRO Champion Program and is excited to recognize the first seven healthcare organizations that have committed to this effort. These HRO Champions include: Kaiser Permanente Northern California, Parrish Medical Center (Titusville, Fla.), Hospital Puebla (Puebla, Mexico), Hospitales Star Medica (Mexico City, Mexico), Hospital Materno Infantil Irapuato (Irapuato, Mexico), Hospital de Especialidades Pediatrico Leon (San Jose del Potrero, Mexico) and Hospital Español (Granada, Mexico).
“The pandemic exposed gaps in the global healthcare system, which forced us to examine the processes in place and identify ways we can prioritize patient safety,” stated Dr. Mike Ramsay, CEO of PSMF. “We are proud to recognize and unite healthcare systems that share this mission and provide them resources to help improve their processes and eliminate preventable harm in their organizations.”
The new HRO Champions program puts an emphasis on data transparency, as this is a critical component to achieving zero harm and improving patient safety. To participate, hospitals and healthcare organizations commit to sharing their adverse event and near-miss data, once annually, to measure the impact of improvements in the network over time. Not only does transparency hold health systems accountable, but it also makes it easier for patients to access safety information to make informed healthcare decisions.
“We are honored to have been designated as HRO Champions by the Patient Safety Movement Foundation, in which we have found a valuable ally to continue improving our care processes,” stated Jose Testas Anton, vice president of Hospital Español. “At Hospital Español, we believe that being able to share and collaborate with other health systems and provide information related to patient safety outside the walls of our organization will help generate collaborative learning and promote patient safety around the world.”
“We are pleased to be recognized for our unwavering commitment to provide safe and reliable patient care and commend our staff for being strong advocates for and partnering with their patients to prevent unnecessary harm,” said Robin Betts, vice president of safety, quality and regulatory services for Kaiser Permanente Northern California. “Our hospitals are among the country’s highest performing for minimizing patient injuries, medication errors and infections. We have processes in place, which closely align with the Patient Safety Movement Foundation to highlight potential safety issues for our care teams who focus every day on protecting the health of their patients, keeping them safe from harm and providing the highest quality care.”
By committing to zero harm, healthcare organizations are eligible for many different benefits, including free coaching, workshops, publicity and other tools. HRO Champions are announced every month and can submit data any time throughout the year to be eligible. Learn more about how to become a HRO Champion: https://patientsafetymovement.org/take-action/organizational-action/going-above-and-beyond/hro-champions/
About the Patient Safety Movement Foundation: Each year, more than 200,000 people die in U.S. hospitals and more than three million globally as a result of unsafe care. The Patient Safety Movement Foundation (PSMF) is a global non-profit with a vision to eliminate preventable patient harm and death across the globe by 2030. PSMF unites patients, advocates, healthcare providers, medical technology companies, government, employers and private payers in support of this cause. From its Actionable Patient Safety Solutions and industry Open Data Pledge to its World Patient Safety, Science & Technology Summit and more, PSMF won’t stop fighting until it achieves zero. For more information, please visit patientsafetymovement.org, and follow PSMF on LinkedIn, Twitter, Instagram and Facebook.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005553/en/
Contact information
Leslie Licano, Beyond Fifteen Communications, Inc.
psmf@beyondfifteen.com | (949) 733-8679 ext.101
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 14:02:00 EEST | Press release
SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased precision and control provided by the system help operators optimize reservoir access, improve production performance and maximize recovery. "Operators are asking int
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 14:01:00 EEST | Press release
Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI can reason over. For customers, this means research that surfaces the right authority faster, answers with even clearer reasoning and sources, drafting guided by matter-specific context, and great
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
European Commission Approves DAYBU ® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union24.8.2026 10:01:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the European Commission (EC) has granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older, making it the first and only treatment approved for Rett syndrome in the European Union (EU). “The approval of DAYBU marks a significant milestone for the Rett syndrome community in the EU and advances our mission to bring this innovative treatment to patients and families who have long faced a profound unmet medical need,” said Catherine Owen Adams, Acadia’s Chief Executive Officer. “For people living with Rett syndrome, a devastating rare neurodevelopmental disorder, there have been no approved treatment options in the EU. We are proud to make DAYBU available and look forward to supporting patients, caregivers, and healthcare providers gain access to treatment." The DAYBU marketing authorization in the EU is prim
ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 124.8.2026 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine originated in Takeda's laboratories in Japan. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available as quickly as possible. “Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1,” said Julie Kim, president and chief executive officer of Takeda. “With the potential to redefine narcolepsy type 1 care, ORZEYFUL is the first validation of our broader orexin strategy, demonstrating how scientifi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
